ArticleJournal of pharmaceutical policy and practice2026
Ownership changes in the pharmaceutical industry: understanding the 2023 pharma mergers and acquisitions landscape of Europe.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pharmaceutical industry is experiencing significant transformations driven by mergers and acquisitions (M&A), leading to complex debates regarding their impact on innovation. This study examines the intricate relationship between M&A activities and innovation within the sector, analysing whether the traded firms have received public funding and revealing diverse scholarly perspectives on the balance of benefits and drawbacks. Methods: We conducted a targeted literature search for a narrative review using a combination of various terms in academic databases (PubMed), complemented by grey literature to find studies that analysed the impact of M&A on R&D. For the case study on the European pharmaceutical M&A landscape of 2023, we used the proprietary database Orbis to find such deals. We then combined information from company websites, investor news, governmental funding agencies, academic news, and academic publications to find public spending for the companies that were acquired in 2023 and used a category system we developed for public contributions. Results: Existing literature suggests that M&A in pharmaceuticals is primarily motivated by technological and geopolitical shifts. However, concerns about market concentration during the drug discovery-to-development pathway highlight potential regulatory challenges. Our analysis of 2023 M&A deals shows that four out of 29 firms traded originated from academic spin-outs, with almost all small and medium enterprises (SMEs) involved having received public funding at some point (18 out of 21). Conclusion: The lack of a comprehensive, publicly accessible register for such contributions complicates analysis. We advocate for mandatory reporting of all publicly funded projects to a single agency, enhancing transparency. The study concludes that while M&A activities can foster innovation, they also pose risks that must be carefully managed through informed policy and regulatory frameworks, particularly concerning publicly funded biotech firms and academic spin-outs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.